Abstract: In a number of clinical conditions such as intoxication, bacteraemia or autoimmune diseases the removal of the disease-causing factor from blood would be the most direct cure. However, physicochemical characteristics of the target compounds limit the applicability of classical filtration and diffusion-based processes. In this work, we present a first in vivo magnetic blood purification rodent animal model and demonstrate its ability to rapidly clear toxins from blood circulation using two model toxins with stable plasma levels (lead (Pb(2+)) and digoxin). Ultra-strong functionalized metal nanomagnets are employed to eliminate the toxin from whole blood in an extracorporeal circuit. In the present experimental demonstration over 40% of the toxin (i.e. lead or digoxin) was removed within the first 10 minutes and over 75% within 40 minutes. After capturing the target substance, a magnetic trap prevents the toxinloaded nanoparticles from entering the blood circulation. Elemental analysis and magnetic hysteresis measurements confirm full particle recovery by simple magnetic separation (residual particle concentration below 1 g mL(-1) (detection limit)). We demonstrate that magnetic separation-based blood purification offers rapid blood cleaning from noxious agents, germs or other deleterious materials with relevance to a number of clinical conditions. Based on this new approach, current blood purification technologies can be extended to efficiently remove disease-causing factors, e.g. overdosed drugs, bacteria or cancer cells without being limited by filter cut-offs or column surface saturation. In a number of clinical conditions such as intoxications, bacteremia or autoimmune diseases the removal of the disease-causing factor from blood would be the most direct cure. However, physicochemical characteristics of the target compounds limit the applicability of classical filtration and diffusion-based processes. In this work, we present a first in vivo magnetic blood purification rodent animal model and demonstrate its ability to rapidly clear toxins from blood circulation using two model toxins with stable plasma levels (lead ions and digoxin).
In a number of clinical conditions such as intoxications, bacteremia or autoimmune diseases the removal of the disease-causing factor from blood would be the most direct cure. However, physicochemical characteristics of the target compounds limit the applicability of classical filtration and diffusion-based processes. In this work, we present a first in vivo magnetic blood purification rodent animal model and demonstrate its ability to rapidly clear toxins from blood circulation using two model toxins with stable plasma levels (lead ions and digoxin).
Ultra-strong functionalized metal nanomagnets are employed to eliminate the toxin from whole blood in an extracorporeal circuit. After capturing the target substance, a magnetic trap prevents that the toxin-loaded nanoparticles enter the blood circulation. In the present experimental demonstration over 40% of the toxin (i.e. lead or digoxin) was removed within the first 10 minutes and over 75% within 40 minutes. Elemental analysis and magnetic hysteresis measurements confirm full particle recovery by simple magnetic separation. We demonstrate that magnetic separation-based blood purification offers rapid blood cleaning from noxious agents, germs or other deleterious materials with relevance in a number of clinical conditions. Based on this new approach, today's blood purification can be extended to efficiently remove disease-causing factors, e.g. overdosed drugs, bacteria or cancer cells without being limited by filter cut-offs or column surface saturation.
Introduction
While current therapeutic approaches are mostly based on the principle of antagonization or neutralization of a particular compound, elimination of the disease-causing factors would represent the most direct conceivable treatment. [1] Procedures removing compounds are routinely performed in patients suffering from renal insufficiency, where waste products are cleared by hemodialysis or hemofiltration. [2] However, the use of size selective separation limits the applicability of such techniques to mostly low-molecular weight compounds, e.g., potassium, urea and creatinine. With continuing identification of new disease-causing factors with higher molecular weight, i.e. proteins, antibodies or endotoxins, there is a great demand for new technological solutions to access these compounds. [3] Recently, we and others have proposed a highly selective separation of target compounds from whole blood using functionalized magnetic nanoparticles. [4] [5] [6] In the magnetic blood purification process, circulating target compounds bind to capturing agents immobilized on tiny magnetoresponsive particles before the loaded nanoparticles are re-collected by magnetic separation.
In contrast to classical purification processes using membranes or porous adsorbents, nanoparticles offer a high external surface area where capturing agents (e.g. antibodies) can be immobilized at a high density on the outermost surface layer, avoiding pore diffusion and providing excellent accessibility for the target. [7, 8] This geometry translates into highly efficient fluid purification, even for high molecular weight compounds with low diffusivity.
In vitro removal of heavy metal ions (lead, [6, 9] cadmium, [10] uranyl ions [5] ), small molecule drugs (diazepam, [4] digoxin [6] ), endotoxins, [11, 12] inflammatory mediators [6, 13] or cells [14, 15] from plasma or whole blood samples has been reported. However, (long-term) risks and possible side effects associated with the use of nanoparticles in vivo are not yet completely understood. [16] [17] [18] [19] Hence, an extracorporeal setting is preferred at this stage as it prevents nanoparticles from entering the body through the blood circuit: Nanoparticles are injected into an extracorporeal loop to promote removal of target compounds. Prior to re-circulation of the blood into the body, a magnetic trap collects the particles, allowing for a continuous extracorporeal blood cleaning process. [13] Although the number of in vitro studies investigating the removal of compounds from whole blood by magnetic separation has increased rapidly in the last five years, [20] the concept has not yet been translated into an in vivo model. The implementation into a feasible in vivo process has most likely been constrained by the use of weakly magnetic particles hampering recovery, and the limited blood circulation time of intravascularly applied nanoparticles. [21] In addition, blood coagulation issues and the limited blood volume of rodents may have prevented rapid advances in the field. [22] Here, we present an in vivo magnetic blood purification rodent animal model and demonstrate its ability to rapidly clear toxins from blood circulation. Based on this new technology, new therapeutic targets may be accessed by blood purification.
Results and Discussion
In this work, for the first time we show the successful implementation of a magnetic nanoparticle-based blood purification technology in a rodent animal model. As both the surface loading (number of functional groups per surface unit) and recovery of magnetic particles are key determinants critical to the process efficiency, ultra-strong magnetic nanoparticles with non-oxidic iron cores are used as magnetic carriers.
Synthesis and Properties of Functionalized Nanomagnets.
Carbon-encapsulated platinumspiked iron carbide (C/Fe 3 C) nanomagnets were synthesized using a flame spray synthesis process. [23] Addition of acetylene (C 2 H 2 ) to the flame enabled in situ carbon-coating of the nanoparticles thus preventing oxidation of the iron-based core and corresponding loss of magnetism. Synthesized nanomagnets are highly magnetic with saturation magnetizations of ~123 emu/g. Platinum is used as tracer to facilitate particle detection by elemental analysis even in complex and iron-rich matrices. The outermost carbon layer surrounding the highly magnetic core was covalently functionalized with target-specific capturing moieties. In this first experimental demonstration, heavy metal ions (lead, Pb 2+ ) and digoxin (small molecule drug) served as model compounds having stable plasma levels and commercially available capturing moieties (iminodiacetic acid-based chelator and digoxin antibody FAB (digiFAB)) ( Figure 1 ). Nanomagnets carrying target-specific capturing agents were dispersed in saline, a physiological carrier fluid to enable continuous injection into the circulating blood. Blood was pumped through the extracorporeal circuit with a total extracorporeal volume of 2.8 mL at a flow rate of 1.5 mL/min and functionalized magnetic nanoparticles were continuously injected into the circulating blood through a silicone injection port at a flow rate of 0.75 mg/min to reach a final concentration of 0.5 mg nanoparticles per mL blood, i.e. about 30 mg in total for one experiment. Before the blood entered the external jugular vein, the nanomagnets were collected and separated from the re-circulating blood by a magnetic separation unit (gradient field induced by a permanent magnet). Animals undergoing the same procedure without injection of functionalized nanomagnets but of pure saline instead served as controls to account for variations in plasma concentration due to dilution (extra volume added by nanomagnet injection) and tissue accumulation/metabolism/excretion. During the experiment, blood samples were sequentially collected every ten minutes and analyzed for remaining toxin concentrations by well-established assays used in clinical diagnostics. [24, 25] Toxin Concentration Measurements. Lead ion plasma levels were found significantly decreased in animals undergoing magnetic separation based blood purification using targetspecific nanomagnets compared to saline treated control animals (lead: p<0.01, N=5) ( Figure   2b ). An additional control experiment using non-functionalized nanomagnets (no binding sites for lead ions) demonstrated a complete lack of purification. Similarly, digoxin could be rapidly removed from blood using digoxin-specific nanomagnets (p=0.0286, N=5) ( Figure   2c ). For both model compounds, over 40% of the toxin was removed within the first 10 minutes (p<0.001) and over 75% within 40 minutes. Toxin plasma levels in control animals remained relatively stable over a time period of 40 minutes, with a decrease by 10% for lead and 32% for digoxin, respectively.
Extracorporeal Magnetic Separation-based
Magnetic Separation of Nanomagnets before Blood Recirculation. To verify how efficiently nanomagnets were eliminated from the blood stream, blood was collected after the magnetic separation unit and analyzed for residual particle concentration measuring the platinum content after chemical digestion by inductively coupled plasma-mass spectrometry (ICP-MS). The platinum concentration in the blood sample after the magnetic separation unit was found below limits of detection (detection limit of platinum in whole blood: ≤1 ng platinum per mL corresponding to ≤1 µg nanoparticles per mL blood) (Figure 2d) . Analysis of magnetic properties of whole blood samples, i.e. hysteresis measurements, showed that blood before the magnetic separation unit exhibited ferromagnetic properties while after the separation unit, blood samples were diamagnetic (Figure 2e ). This discrete change in properties is in good agreement with elemental analysis and confirms the high separation efficiency using a magnetic separator with simple geometry. Thus, magnetic measurements, in contrast to elemental analysis, enable identification of the iron phase of interest (i.e. intact 
Conclusions
In summary, we present an easily applicable implementation of a nanomagnet-based blood purification process in a first in vivo detoxification model. Blood can be successfully purified in an extracorporeal blood purification circuit using functionalized nanomagnets as capturing moieties. Remarkable separation efficiencies are achieved even by a simple magnetic separation unit using a single permanent magnet. Hence, in vivo magnetic separation-based blood purification is a potent new method to selectively remove noxious compounds from blood not limited by size-selection criteria. This new technological solution provides the basis for new therapeutic targets and may be extended to selectively isolate disease causing factors such as overdosed drugs, proteins, endotoxins, bacteria (e.g. in sepsis) or cancer cells in a clinical setting.
The extracorporeal application of nanoparticles can be considered as a first step towards a safe implementation of nanomagnet-based treatments provided that safety barriers are implemented. Iron-based particle detection in complex and iron-rich matrices presents a major challenge even for the best available elemental analytics devices. Magnetic hysteresis measurements offer a valuable alternative complementing elemental analysis without requiring nanoparticle digestion. With regard to a future clinical application, the magnetic separation efficacy is pivotal: a safe implementation of this young technology relies on minimal risk policy by limiting direct exposure to nanomagnets and a detailed risk evaluation.
This includes assessment of acute and long-term adverse effects and more advanced particle detection methods. [1, 26, 27] 
Materials and Methods

Synthesis and characterization of carbon encapsulated platinum-spiked iron carbide
nanomagnets: Carbon encapsulated platinum-spiked iron carbide nanomagnets were synthesized using flame spray synthesis under reducing atmosphere (detailed synthesis procedure can be found elsewhere) [28] . Briefly, iron and platinum precursors were synthesized by dissolving iron nitrate and platinum acetylacetonate in 2-ethylhexanoic acid, respectively. The precursors were mixed to have a mass content of 0.1% platinum, diluted with tetrahydrofurane (THF, Fluka, technical grade, 2:1) and filtered. Carbon encapsulated platinum-spiked iron carbide nanoparticles were synthesized in a flame spray synthesis reactor under nitrogen atmosphere. The precursor was fed into the spray nozzle at a flow rate of 6 mL/min. Acetylene (Pangas) was added at a flow rate of 5 L/min to obtain in situ coating of the nanoparticles. As-prepared nanoparticles were thoroughly washed in 24 vol% hydrochloric acid (HCl, Fluka, puriss) to dissolve incompletely coated nanoparticles. The platinum content was measured using inductively coupled plasma mass spectrometry (ICP-MS, Element2, Thermo-Finnigan, Bremen, Germany) Magnetic hysteresis measurements were performed on a vibrating sample magnetometer (VSM, Princeton Measurements Corporation, model 3900) using a 100 ms averaging time.
Chemical functionalization: For lead-ion selective functionalization, nanomagnets were coated with poly(ethylene imine) (PEI)-iminodiacetic acid (IDA). Before branched PEI (10 kDa, Polysciences Inc., 99%) was physisorbed on the carbon shell encapsulating the nanoparticles, the particles were washed in H 2 O (Millipore) and DMF (Fluka, puriss), respectively. PEI was dissolved in dimethylformamide (DMF), added to nanoparticles predispersed in DMF and stirred overnight. Then, the nanoparticles were washed in DMF, water and acetone (Fluka, puriss) three times each and dried in vacuum. Subsequently, nanoparticles (100 mg) were dispersed in DMF (100 mL), and potassium hydroxide (0.2 g, Sigma Aldrich) and bromoacetic acid (0.1 g, Sigma Aldrich) were added. The mixture was stirred at 90°C-110°C and 5 mL of H 2 O were added. Nanoparticles were separated from the dispersion, and vein were surgically exposed and two sutures (6-0 silk), proximal and distal, were placed around the vessels. First, the distal suture of the carotid artery was retracted followed by a small incision into the ventral vessel wall, where the catheter was inserted and stabilized using the second silk suture. Blood was pumped into the extracorporeal circuit (pump from H.J.
Guldener, Zurich, ZU/83W, 12082). The opponent ending of the tubing system was inserted into the external jugular vein and blood was pumped through the circuit at a flow rate of 1.5 mL/min. Flow conditions and the total extracorporeal volume were adapted from Adachi et al. [29, 30] . Experimental groups include at least five animals each (N=5).
Toxin concentration measurements:
The first blood sample was collected 10 minutes after intravenous administration of the toxin in the jugular vein before magnetic blood purification was started. Subsequently, blood samples of 0.5 mL were collected every 10 minutes. Blood samples were analyzed for remnant toxin concentrations using Atomic Absorption Spectrometry (AAS) for lead ions [24] and a kinetic interaction of microparticles in solution assay (KIMS, Roche Diagnostics) for digoxin [25] .
Nanoparticle concentration measurements: Nanoparticle residues were determined using two complementary methods, elemental analysis and magnetic hysteresis measurements. For ICP-MS measurements (Element2, Thermo Fisher Scientific, Bremen), biological samples (blood and tissues) were digested using hydrochloric acid (conc.), nitric acid (conc.), hydrogen peroxide (30%) at 200 °C and 40 bar ensuring total dissolution of all particles and the biological matrix. Platinum contents were then determined using ICP-MS. Magnetic hysteresis measurements of freeze-dried blood samples (CHRIST Alpha 1-4 freeze dryer, <0°C/<6.1 mbar) were performed on a vibrating sample magnetometer (VSM, Princeton Measurements Corporation, model 3900) using a 100 ms averaging time.
Histology: In all groups, following blood purification, organs were procured and lung and liver tissue was analyzed using standard formalin fixation and H&E staining methods. before the magnetic separator, the blood exhibits ferromagnetic properties while after separation it is diamagnetic (e). 
